AstraZeneca partners with Oracle to bring AI into clinical trials

Oracle announced that it has signed a non-binding agreement with AstraZeneca to test the potential for AI and real world patient data to find trial-eligible patients faster, aimed at easing recruitment, which remains the biggest bottleneck in drug research. The announcement came from Oracle’s corporate newsroom , with AstraZeneca also issuing its own release the same day. The partnership brings together pharmaceutical giant AstraZeneca and Oracle’s health data, cloud, AI, analytics and clinical workflow tools. Oracle described the arrangement as an agreement to “explore” selected use cases, and not as a binding commercial contract, leaving both companies free to walk away if the initial setup fails to deliver results.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to Cryptopolitan.